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Abstract 
We report results from three independently conducted studies on the prevalence of cancer in restless 
legs syndrome (RLS) cases and non RLS cases. Already in 1955 Ekbom observed RLS in patients with 
subsequently detected cancer. Since then only three case reports and one article assessed the relationship 
between RLS and cancer patients undergoing chemotherapy. The observed proportion of RLS in these 
cancer patients (18.3%) was about twice as high as in general population studies. Two of our studies were 
general population based studies (Dortmund Health Study (DHS); Study of Health in Pomerania (SHIP)) 
and one was performed among members of the German and Swiss RLS patient organizations (Course of 
Restless Legs Syndrome-Study (COR-S)). Additionally we used data from the population based, regional 
cancer registry of the Muenster district for comparisons. Our data show that in all three studies the 
prevalence of cancer was higher in RLS cases than in non cases for both genders. In two of the studies the 
increased risk was in part explained by age. The data of the COR-Study revealed a statistically significant 
higher risk for cancer in RLS subjects compared to the population based data of the regional cancer registry 
of Muenster. Our results suggest a higher proportion of cancer among RLS cases compared to individuals 
without RLS. Given an RLS prevalence of about 5 to 10 percent in the general population, a need to rule 
out cancer in patients with a new onset of RLS, especially among the elderly patients is important.
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Introduction 
Restless legs syndrome (RLS) is a common sleep disorder 
with a prevalence of 5% to 10% in the general population of 
Western countries [1–4]. Applying the four minimal criteria [5,6] 
published by the International RLS study group (IRLSSG) studies 
found an increasing prevalence with age [1,7] and women 
being approximately twice as often affected as men [2,8,9]. In 
1955 Karl Axel Ekbom was the first to report a finding of RLS in 
patients with anemia [10], sometimes preceding the definitive 
diagnosis of cancer. Cancer prevalence also increases with age. 
For many types, cancer incidence and mortality is higher in 
men than in women [11]. However, due to a better survival of 
women [12], their overall prevalence of cancer is higher [13].
Due to the demographic change with a growing number 
of older people, both diseases will gain importance. Although 
there are a number of cross sectional studies reporting higher 
prevalences of non-cancer conditions, such as diabetes, an 
increased body mass index [2,7] and cardiovascular risk factors 
or diseases [1,14] in RLS cases compared to non cases, cancer 
prevalence in RLS patients, has not yet been studied in a similar 
comprehensive approach. Up to now only two further case 
reports [15,16] and a recent study that assessed the prevalence 
of restless legs syndrome in cancer patients undergoing 
chemotherapy are published [17]. The aim of our analysis was 
to evaluate the prevalence of cancer in individuals with and 
without RLS in three large independent studies in Germany.
Materials and methods
Data from three studies, independently conducted in Germany 
between 2002 and 2007, were used. Two of them were general 
population based epidemiologic studies the third one was 
performed among members of the German and Swiss RLS 
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patient organizations.
The Dortmund Health Study (DHS) [18] was conducted 
in the city of Dortmund in the western part of Germany. For 
examinations and interviews, a random sample from the 
respective population register, stratified by age and gender, 
was drawn. 3820 individuals, aged 25-75 years were invited 
of whom 395 persons were not eligible due to death, moving 
or lack of sufficient knowledge of the German language to 
sign informal consent. Baseline assessment was done in 2003 
and 2004. The initial response rate was 66.9%, yielding 2291 
participants. If a personal participation in the study centre 
was not possible, a questionnaire with a subset of otherwise 
identical questions was mailed to the participants. Due to 
reduced space available in the questionnaire, RLS criteria 
assessment was restricted to interview participants only. 
Thus, for the purpose of this analysis, only data of participants 
attending the personal interview at the study centre (n=1312) 
were included.
The Study of Health in Pomerania (SHIP) [2], a population-
based study in the north-eastern part of Germany, was started 
by the University of Greifswald in 1997. Participants aged 20-
79 years, were drawn randomly from the regional population 
registration offices, stratified by age and gender. The baseline 
assessment (SHIP) was done between 1997 and 2000 with a 
baseline response of 68.8%, yielding 4310 participants. The 
first follow-up after 5 years, conducted between 2002 and 
2006 (SHIP-1) included a total of 3300 individuals (follow-up 
response rate 83.6%) aged 25-88 years. We used the data 
from this first follow-up for the analysis.
The Course of Restless Legs Syndrome-Study (COR-S) was 
started in 2007. All 4385 members of the German RLS patient 
organisation (RLS e.V. Deutsche Restless Legs Vereinigung) and 
633 members of the Swiss patient organisation (Schweizeris-
che Restless Legs Selbsthilfegruppe) were once contacted 
and invited to participate in the study. 2562 members of 
the German association (response proportion 58.4%), and 
254 members of the Swiss patient organisation (response 
proportion 40.1%) accepted the invitation and were recruited 
into the study. 65 individuals became ineligible in the short 
period of time between invitation and questionnaire due 
to death, delayed refusal or moving. Thus, the COR-Study 
population included 2751 individuals, aged 26-96 years with 
an overall participant response of 56.1%. 168 of the 2510 
German participants had undergone a standardized, detailed 
diagnostic work up in one of five specialized RLS centers. 
Inclusion of these participants enabled the definition of a 
group with a diagnostic `gold standard`.
Since the COR-Study is conducted among RLS cases only, we 
used data from the population based, regional cancer registry 
of the Muenster district (Epidemiologisches Krebsregister NRW 
gGmbH) for comparisons. Being attached to the International 
Agency for Research on Cancer (IARC), the cancer registry 
collects data on the frequency and distribution of cancer in 
the area. For comparisons the 10-year prevalence of cancer 
was used, including all subjects who were diagnosed with 
cancer and survived during the period from 1994 to 2004 in 
the district of Muenster. These data were either collected by 
pathologists or had been reported by the treating hospital.
In DHS and SHIP RLS was diagnosed according to the minimal 
criteria published 1995 by the IRLSSG. Face to face interviews 
in both studies included identical questions for RLS that had 
been validated against physician classification [19] and been 
used in identical form before [3]. The three questions included: 
1) Do you have sensory discomfort like tingling, crawling with 
ants or pain in the legs associated with an urge to move? 
2). Do these symptoms occur at rest i.e., while sitting down 
or falling asleep, and do they improve by moving? 3) Are 
these symptoms worse in the evening or at night, compared 
with the morning? The answer categories were in all cases 
`Yes`, `No` or `I don`t know`. To be diagnosed as RLS positive, 
participants had to answer all three questions with `Yes`. In 
addition symptom frequency was assessed in both studies.
Only DHS participants were additionally asked if a physician 
had ever diagnosed RLS. These individuals (n=19) were 
categorized as RLS positive, even if they did not fulfill the 
minimal criteria at the time of the interview. Data on the 
self-reported history of cancer, including the type of cancer, 
frequency of cardiovascular risk factors and disorders and 
other comorbidities were collected in DHS and SHIP-1.
The baseline questionnaire of the COR-Study covered 
questions about medical history, diagnostic methods, 
duration of RLS symptoms and socio-demographic data. 
Other comorbidities including cancer were assessed. In case 
of a positive cancer history, additional information about the 
type of cancer, the year of diagnosis and resulting therapies 
were collected. No validation of the participant’s self-report 
of cancer was done. However, in case of contradictory in-
formation, e.g., breast cancer in men, additional information 
was collected by telephone and the corrected data were used. 
With regard to the international classification of diseases, 10th 
revision (ICD-10) all cancer types were included except the 
non melanoma skin cancer (ICD C44). Participants with this 
type of cancer were not coded as cancer cases.
Only in the COR-Study the German version of the Inter-
national RLS study group severity scale (IRLS) was used as 
a validated scale [20] to assess the severity of RLS. Ethics 
statement: The study protocol of the COR-Study was approved 
by the local ethics committee of the Medical Faculty at the 
University of Muenster.
Statistical analysis
All analyses were done separately in the three studies. 
Differences in cancer prevalences between RLS positive and 
RLS negative individuals in each study were compared using 
Chi-square test or Fischer`s exact test if the cell number was 5 
or less. Logistic regression was used to determine unadjusted 
as well as age and gender adjusted odds ratios for cancer in 
each study. To assess age adjusted odds ratios comparing 
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data from the cancer registry and the COR-Study, we used 
the Mantel-Haenszel method. All analyses were done with 
STATA 9.0 (StatCorp LP, College Station, TX, USA).
Results
In total 7363 adults participated in these three independent 
studies, 2751 in the COR-Study, 1312 in DHS and 3300 in SHIP-1. 
Table 1 summarizes the characteristics of all participants 
stratified by study. Due to different age inclusion criteria, 
age ranges of the recruited participants differed between 
studies. Mean age was highest in the COR-Study with 65.9 
years. 71.6% of the participants in the COR-Study and about 
50% in the other two studies were women. The prevalence of 
RLS in DHS was 8.8% (10.2% in women and 7.2% in men) and 
10.5% in SHIP-1 (13.6% in women and 7.2% in men). 4.3% of 
the participants of DHS reported a diagnosis of cancer, 5.2% 
of the women and 3.3% of the men. In SHIP-1 overall 4.7% 
self-reported a cancer diagnosis, 4.4% of the female and 4.9% 
of the male participants. In contrast, 12.5% of the COR-Study 
participants reported cancer, 12.1% of the women and 13.4% 
of the men.
Dortmund
DHS
n=1312
Pomerania
SHIP-1
n=3300
Course of  
RLS Study
COR-Study
n=2751
Mean age (range), years 52.1 (25-74) 54.5 (25-88) 65.9 (27-96)
Mean age women (range), years 51.1 (25-74) 53.5 (25-88) 65.5 (29-96)
Mean age men (range), years 53.3 (25-74) 55.5 (25-86) 66.9 (27-94)
Women, % 52.9 51.9 71.6
Prevalence of RLS, % 8.8 10.5 100.0
Women, % 10.2 13.6 100.0
Men, % 7.1 7.2 100.0
Prevalence of cancer¹, % 4.3 4.7 12.5
Women, % 5.2 4.4 12.1
Men, % 3.3 4.9 13.4
Known diagnosis of  
hypertension2, % 35.2 50.4 46.4
Known diagnosis of diabetes2, % 7.6 11.2 10.7
History of myocardial  
infarction2, % 3.7 4.3 5.0
Body mass index≥303, % 26.4 30.4 18.8
Table 1. Characteristics of the participants in the three studies  
(DHS, SHIP-1 and COR-Study).
¹excluding non-melanoma skin cancer 
2self-reported physician diagnosis
3based on self-reported (COR-Study) or measured 
 (DHS and SHIP1) height and weight
Tables 2 and 3 provide the cancer prevalences according to 
age and gender separately in the three studies. A consistent 
higher prevalence of cancer in both genders and all age 
DHS SHIP-1 COR- 
Study
Cancer 
 registry1
Age group RLS+ RLS- RLS+ RLS- RLS+ --
<34 years, % 33.3 1.3* 0 0 0 0.2
35-44 years, % 0 0 0 0.8 0 0.5
45-54 years, % 0 1.8 4.6 1.4 4.5 1.0*
55-64 years, % 7.1 2.0 5.0 4.5 8.6 3.2*
65-74 years, % 7.1 8.2 12.1 10.0 9.8 7.0
75+ years, % -- -- 21.1 10.8 27.8 10.1*
TOTAL, % 7.0 3.0 8.7 4.6* 13.4 1.9*
OR, unadjusted 
(95% CI) 2.45 (0.69-8.72) 2.00 (1.00-4.00) 8.23 (6.64-10.13)
OR, age adjusted 
(95% CI) 1.98 (0.54-7.18) 1.62 (0.79-3.31) 2.44 (1.98-3.01)
Restricted to age group 25-74 years:
TOTAL, % 7.0 3.0 6.3 3.7 8.2 1.4*
OR, unadjusted 
(95% CI) 2.45 (0.69-8.72) 1.76 (0.73-4.22) 6.33 (4.59-8.54)
OR, age adjusted 
(95% CI) 1.98 (0.54-7.18) 1.31 (0.53-3.22) 1.82 (1.35-2.47)
Table 2. Prevalence of cancer in male RLS cases and non cases 
according to age group and study.
*p<0.05 for the comparison within the age stratum  
(Chi Square Test) ¹RLS prevalence in the source population 
(n=1,280,314 in 2004) unknown
DHS SHIP-1 COR- 
Study
Cancer  
registry1
Age group RLS+ RLS- RLS+ RLS- RLS+
<34 years, % 0 0 11.1 0* 0 0.2
35-44 years, % 6.7 3.1 2.7 2.4 5.8 0.8*
45-54 years, % 8.3 2.1 0 4.1 11.0 2.1*
55-64 years, % 15.0 8.5 8.6 3.3* 4.0 3.8*
65-74 years, % 11.1 8.8 7.1 6.4 11.8 5.1*
75+ years, % -- -- 12.5 11.6 13.1 6.1*
TOTAL, % 9.9 4.7 6.5 4.1 12.1 2.1*
OR, unadjusted 
(95% CI) 2.24 (0.94-5.32) 1.63 (0.91-2.92) 6.61 (5.76-7.59)
OR, age adjusted 
(95% CI) 1.93 (0.80-4.65) 1.34 (0.74-2.42) 2.97 (2.59-3.40)
Restricted to age group 25-74 years:
TOTAL, % 9.9 4.7 5.8 3.3 11.9 1.6*
OR, unadjusted 
(95% CI) 2.24 (0.94-5.32) 1.80 (0.93-3.46) 8.33 (7.14-9.72)
OR, age adjusted 
(95% CI) 1.93 (0.80-4.65) 1.47 (0.76-2.86) 3.17 (2.72-3.69)
Table 3. Prevalence of cancer in female RLS cases and non cases 
according to age group and study.
* p<0.05 for the comparison within the age stratum 
 (Chi Square Test) ¹RLS prevalence in the source population 
(n=1,344,175) unknown
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COR-Study Cancer registry²
N % N %
overall cancer 344 12.5 51167 1.95
women, total 239 12.1 27520 2.05
breast 102¹ 5.2¹ 12006 0.89
other cancers 147¹ 7.5¹ 15514 1.15
men, total 105 13.4 23647 1.85
prostate 48¹ 6.1¹ 8040 0.63
other cancers 65¹ 8.3¹ 15607 1.22
Table 4. Prevalence of cancer subtypes in the Course of 
RLS-Study and the cancer registry.
Data from the cancer registry concerning history of more than 
one type of cancer were not available. In a second step we 
analyzed if RLS severity was related to cancer prevalence in 
the COR-Study. However, after adjustment for age and gender 
no difference in mean severity between RLS subjects with 
and without cancer was noted (OR 1.01, 95% CI 0.99, 1.02). 
Also, when the RLS severity score was broken down in five 
categories of increasing severity, the proportion of individuals 
¹>1 carcinoma (COR-Study n=17 
(one triple carcinoma)=4.9%)  
²>1 carcinoma n unknown
with cancer in each category was not significantly different, and, 
thus, no trend of higher cancer prevalences with increasing 
RLS severity was found (ptrend=0.13).
Considering the question of the onset of cancer versus the 
onset of RLS, more than 73% of the COR-Study participants with 
cancer reported RLS symptoms before the cancer diagnosis. 
21.8% had a cancer diagnosis before onset of RLS symptoms 
and 4.4% reported the onset of both diseases in the same year. 
Moreover, cancer therapy can be considered as a possible cause 
for the induction of RLS in participants with a primary cancer 
diagnosis. 39.4% of all participants with a cancer diagnosis had 
received radiotherapy and 27.7% had chemotherapy. 19.7% 
of those receiving chemotherapy, developed RLS over the 
course or after finishing chemotherapy. 25.0% of the subjects 
receiving radiotherapy, complained about RLS symptoms 
during or after application of the radiotherapy.
Discussion
We compared the prevalence of cancer between RLS cases 
and non cases in three large and independently conducted 
studies in Germany. The main finding of this analysis was a 
higher prevalence of cancer in RLS cases compared to non 
cases in all three studies. After stratification by gender a higher 
probability for cancer in RLS subjects in two of the studies 
was explained by age but remained in the third statistically 
significant. No elevated probability for breast cancer was 
found for female participants of the COR-Study. However, 
the probability for prostate cancer in men with cancer and 
RLS was significantly increased.
The causes of RLS are still not entirely understood. Genetic 
factors are supposed to play an important role in the cause 
of idiopathic RLS. In addition several gene loci, identified 
in linkage studies in RLS families [21] and genome-wide 
association studies (GWAS) have revealed intronic or intergenic 
regions of the four genes BTBD9 [22], MEIS1 and LBXCOR1/
MAP2K5 [23], which are supposed to be involved in up to 70% 
of all genetic RLS cases [24] and PTPRD, recently [25]. Lower 
serum ferritin levels are also associated with BTBD9 [22]. A 
potential role of these loci for the onset of cancer is unclear 
and has to be determined.
Prostate cancer is the most common cancer in men in 
Germany (Robert Koch Institute, 2008). Similar to RLS, familial 
aggregation of prostate cancer is known. Male relatives of 
affected men have a two-fold increased risk for prostate cancer, 
especially if the cancer diagnosis was made before age 60 
years [26]. Lifestyle and environmental related risk factors 
for prostate cancer have not been found yet. Similar to RLS 
prostate cancer is genetically complex and predisposition may 
be passed on through multiple common low-penetrance alleles 
in combination with lifestyle or environmental risk factors 
[27]. Taking recent findings from genetic and epidemiologic 
studies into account, the question arises [28] if prostate cancer 
and RLS share more common biological pathways than only 
low serum ferritin levels and/or anemia.
groups for RLS sufferers was seen in the three studies. The 
overall probability, expressed as the prevalence odds ratio, 
was 8- and 6- fold higher for men and women, respectively, 
in the COR-Study, and roughly two-fold higher for RLS cases 
for both genders in DHS and SHIP-1. After adjusting for age 
however, this probability attenuated considerably and was 
no longer statistical significant in DHS and SHIP-1. For a better 
comparison of the three studies including the cancer registry, 
we set the upper age limit to 74 years (Tables 2 and 3) due to 
the exclusion of participants older than 74 years in DHS. This 
age restriction slightly decreased the possibility of cancer in 
men with RLS in SHIP-1 and COR-S, and increased the one for 
women in both studies. Again, only the odds ratios for the 
COR-Study in comparison with the cancer registry remained 
significant.
Table 4 summarizes the prevalences of breast and prostate 
cancer in the COR-Study and the cancer registry. 43.6% of all 
documented female cancers in the cancer registry were breast 
cancers and 34.0% of all male cancers were prostate cancers. 
The COR-Study revealed similar results for breast cancer with 
42.7% of all cancer types in female participants being breast 
cancer, but a higher proportion of 45.7% prostate cancers 
in men. The likelihood of having a prostate cancer for male 
participants of the COR-Study was higher in comparison to 
male cancer cases in the cancer registry (OR 1.63, 95% CI 
1.08, 2.44). Of all COR-Study participants with a history of 
cancer 4.9% (n=17) suffered from more than one cancer type. 
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Knowledge on risk factors for the onset of RLS from prospective 
studies is still sparse. However, several RLS risk factors are 
hypothesized in cross-sectional studies, such as diabetes, 
an increased body mass index [2,7], hypertension and heart 
problems [1].
In the COR-Study two thirds of the participants with cancer 
developed RLS before their cancer was diagnosed. Chemo- 
and radiotherapy seemed to have no influence on the onset 
of RLS. Three prior articles have discussed the possibility of an 
association between cancer and RLS. Ekbom [10], Brocklehurst 
[15], and Parish [16] presented case reports in which RLS had 
been a symptom of a still unknown malignant disease, due 
to decreased serum ferritin levels caused by occult bleeding 
in the gut or bladder. Thus, so called secondary RLS cases, 
especially, should carefully be evaluated for an early stage 
cancer. In these cases treatment of the respective cancer 
would be a causal therapy. Ostacoli [17], in contrast, assessed 
the prevalence of RLS in cancer patients while undergoing 
chemotherapy. RLS patients were identified by a screening 
questionnaire fulfilling the minimal criteria for RLS, followed 
by a structured interview with a sleep specialist to confirm the 
diagnosis of RLS. They reported a prevalence of RLS of 18.3% 
in these patients, however, did not assess the length of time 
participants had already suffered from RLS symptoms. Thus, 
information about the onset of RLS and the time sequence 
between RLS and cancer is not known. It can be a challenge 
to disentangle the causal pathway and time sequence of 
answered of both conditions in an individual. RLS could be 
second to cancer onset, especially in cancer patients receiving 
chemotherapy. RLS could co-occur shortly before or at cancer 
symptom onset due to shared pathophysiologic pathways 
such as anemia or renal failure. The pathophysiology of RLS 
is not yet completely understood. Iron deficiency as well as 
dopamine dysregulation have shown to play an important 
role on the onset of the disease [29]. Finally, it cannot be 
excluded that RLS is a predictor of some later cancer types, 
e.g., due to common genetic susceptibility. The frequency of 
most cancer types as well as of RLS increases with age. Given 
the demographic changes in most Western countries the 
number of individuals affected by either or both conditions 
will sharply increase over the next decades.
Strengths of our analysis are the inclusion of three indep-
endent large studies enabling to compare the RLS-cancer 
relationship across different study settings and regions. We 
used a standardized assessment of RLS case-status according 
to the minimal criteria of the IRLSSG in two population studies. 
A limitation of this work is that assessment of RLS symptoms 
and the diagnosis of cancer were based on self-reports and 
we can not exclude a misclassification of both conditions. 
However, the RLS classification had prior been validated 
against physician rating [19] and showed a good reliability. 
Also the validity of self reported cancer diagnoses is high due 
to their perceived severity in most cases. Since the COR-Study 
included cases only we used data of a well established cancer 
registry, as controls. The register covered a 10-year prevalence 
only, and might underestimate the prevalence for all types of 
cancer compared to the lifetime assessment done in the other 
studies. The unknown proportion of RLS cases in the cancer 
registry might further cause a slight underestimation of the 
RLS cancer risk. DHS did not include the age group 75+, in 
which the highest prevalence of cancer is generally observed.
In summary our comparisons of the prevalence of cancer 
in RLS cases and non-cases show the need to study the 
relationship between RLS and cancer in detail. Clinically, our 
results emphasize the necessity to rule out cancer in patients 
with a new onset of RLS symptoms, especially among elderly 
patients. Replication of these findings in prospective studies 
are required. From a pathophysiological aspect the question 
arises if both conditions share biological pathways in their 
development which may ultimately provide clues for causal 
therapy approaches. From an epidemiologic perspective 
prospective cohort studies are necessary to disentangle the 
time sequence between both diseases, however, these need 
large sample sizes due to the low cancer incidence under the 
age of 60 years.
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